Helius Therapeutics Launches Two GMP-Certified Medicinal Cannabis Products in New Zealand

Dec.30.2022
Helius Therapeutics Launches Two GMP-Certified Medicinal Cannabis Products in New Zealand
New Zealand company Helius is producing four GMP-certified medicinal cannabis products and plans to export to Europe in 2023.

In New Zealand, two new medicinal cannabis products have been confirmed to meet sales quality standards. Earlier, Helius became the first New Zealand company to receive GMP certification, producing tetrahydrocannabinol extracts and manufacturing medicines containing tetrahydrocannabinol.


Carmen Doran, Chief Executive of Helius Therapeutics, has expressed delight in bringing more medicinal cannabis products that are grown and manufactured in New Zealand to patients. The company will launch two new drugs in the New Zealand market, bringing the total number of new drugs to be launched by Helius in 2022 to four. This means that the company's product portfolio now comprises six products, according to an email sent to Vapor Voice.


In mid-December, we were able to announce GACP certification, and since then, we have also obtained GMP certification for an additional four processes in our East Auckland factory. This progress demonstrates the collaborative culture being established by the Helius team," she said.


Helius is the only company in New Zealand that has received GMP certification for the extraction and manufacturing of CBD and THC drugs. Moreover, it is now one of two companies in the country that has six products that have been verified to meet the minimum quality standards (the other being Nubu Pharma).


The latest product will be exported to Helius clients in Europe in 2023.


Products containing THC have attracted great interest internationally, with GMP-manufactured products gaining widespread attention worldwide as the medical market continues to grow. "We are particularly interested in a balanced full-spectrum medicinal cannabis formula," said Doran.


With the launch of these products, New Zealand patients now have access to a range of locally manufactured oral liquid products. They will no longer have to rely on imported products that may experience supply delays throughout 2022 and may come at a much higher cost.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
Philip Morris International (PMI) plans to invest approximately PHP 4.5 billion ($71 million) to expand its existing smoke-free manufacturing facility in Tanauan, Batangas, in the Philippines. The expansion is expected to be completed in 2027, with additional capacity serving domestic and export markets. The facility began manufacturing heated tobacco consumables in April 2024, including BLENDS sticks for the BONDS by IQOS platform. Philippine business media reported in October 2026 that products from the Batangas plant were being exported to 18 markets across Asia and Europe. PMI says it has invested more than $2 billion in the Philippines since 2010. The expansion adds to the country's existing manufacturing and export role within PMI's international supply chain.
company
Nov.16
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives